Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Antonio González-Martı́n(Clinica Universidad de Navarra), Philipp Harter(Kliniken Essen-Mitte), Alexandra Léary(Université Paris-Saclay), Domenica Lorusso(Università Cattolica del Sacro Cuore), Rowan Miller(University College Hospital), Bhavana Pothuri(NYU Langone Health), Isabelle Ray‐Coquard(Université Claude Bernard Lyon 1), David S.P. Tan(National University Hospital), E. Bellet(Alleanza Contro il Cancro), Ana Oaknin(Vall d'Hebron Institute of Oncology), Jonathan A. Ledermann(University College London)
Annals of Oncology
August 17, 2023
10.1016/j.annonc.2023.07.011
Cited by 373Open Access
Full Text

Abstract

Related Papers

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, Nuala McCabe, Christopher J. Lord et al.|Nature|2005|6.7k
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
Andreas du Bois, Alexander Reuß, Eric Pujade‐Lauraine et al.|Cancer|2009|1.6k
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Amit M. Oza, Adrian Cook, Jacobus Pfisterer et al.|The Lancet Oncology|2015|865
Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial
J. Baptist Trimbos, Ignace Vergote, Giorgio Bolis et al.|JNCI Journal of the National Cancer Institute|2003|688
Association Between <emph type="ital">BRCA1</emph> and <emph type="ital">BRCA2</emph> Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
Kelly L. Bolton|JAMA|2012|670